Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Comparison Tests01:13

Multiple Comparison Tests

4.5K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
4.5K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

677
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
677
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

510
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
510
Kendall's Coefficient of Concordance01:20

Kendall's Coefficient of Concordance

1.1K
Kendall's Coefficient of Concordance (W), also known as Kendall's W, is a non-parametric statistical measure used to assess the agreement or concordance between multiple raters or judges when they rank a set of items. It is often used when you have ordinal data (ranks) and you want to see if there is consistency or consensus among the raters. It is widely applied in research areas such as psychology, medicine, and social sciences, where multiple judges are asked to rank or rate subjects...
1.1K
Hazard Ratio01:12

Hazard Ratio

664
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
664
Receiver Operating Characteristic Plot01:15

Receiver Operating Characteristic Plot

534
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
534

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.

Blood advances·2025
Same author

Study on multi-dimensional dynamic changes and quality control of Aurantii Fructus during the stir-frying with bran process.

Food research international (Ottawa, Ont.)·2025
Same author

Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States.

Lupus·2025
Same author

De novo transcriptome sequencing to identify the neuropeptides and neuropeptide receptors of the paulownia bagworm Clania variegata (Lepidoptera: Psychidae).

Journal of economic entomology·2025
Same author

FAM49B Fragmentation by Asparagine Endopeptidase Promotes Vascular Smooth Muscle Cell Migration in Atherogenesis.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development.

Biostatistics (Oxford, England)·2025

Related Experiment Video

Updated: Mar 5, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers.

Zhiwei Zhang1, Shujie Ma1, Lei Nie1

  • 1.

The International Journal of Biostatistics
|March 27, 2017
PubMed
Summary
This summary is machine-generated.

This study introduces a new statistical method to compare and combine treatment selection markers for precision medicine without needing to set specific cutoff values. This approach enhances personalized treatment strategies by better predicting treatment effects using marker data.

Keywords:
U-statisticcross-validationpersonalized medicineprecision medicinepredictive biomarkertreatment effect heterogeneity

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 5, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Area of Science:

  • Biostatistics
  • Precision Medicine
  • Clinical Trial Methodology

Background:

  • Precision medicine relies on treatment selection markers to personalize patient care.
  • Current methods often dichotomize markers, limiting their utility due to factors like safety and cost.
  • A statistical framework is needed to compare and combine markers without arbitrary cutoff values.

Purpose of the Study:

  • To develop a statistical framework for comparing and combining treatment selection markers.
  • To introduce a quantitative concordance measure for evaluating marker performance.
  • To enable personalized treatment selection without marker dichotomization.

Main Methods:

  • Proposed a quantitative concordance measure to assess marker-predicted treatment effects.
  • Utilized U-statistics for estimating the concordance measure from clinical trial data.
  • Incorporated auxiliary covariates via an augmentation term in the U-statistic.
  • Developed a cross-validation procedure for optimizing marker combinations and mitigating bias.

Main Results:

  • The proposed concordance measure effectively quantifies the predictive power of markers for treatment effects.
  • The methodology was successfully applied to an HIV treatment selection example.
  • Simulation studies demonstrated the robustness and utility of the proposed framework.

Conclusions:

  • The developed statistical framework allows for effective comparison and combination of treatment selection markers.
  • This approach supports more nuanced and personalized treatment decisions in precision medicine.
  • The methodology offers a valuable tool for optimizing treatment strategies based on marker data.